Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
NCT ID: NCT01971190
Last Updated: 2015-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
43 participants
INTERVENTIONAL
2013-10-31
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The pathophysiology of CSC is associated with abnormal choroidal circulation. Indocyanine green angiography (ICGA) has revealed dilated and congested choroidal vessel and leakage into the extracellular space that appears as area of hyperfluorescence seen in middle and late phase in eyes with CSC.
A goal of treatment has been focused on reducing choroidal hyperpermeability. Currently, photodynamic therapy with verteporfin (PDT) and intravitreal anti-VEGF (vascular endothelial growth factor)antibody injection are being tried in order to treat chronic CSC. PDT reduces choroidal hyperpermeability by inducing hypoperfusion of the choriocapillaris in the short term and choroidal vascular remodeling over time. Intravitreal anti-VEGF injection for the treatment of CSC also effectively reduces choroidal hyperpermeability by blocking vascular leakage. Both methods have shown to be effective with good functional outcome for treating chronic CSC in many reports, but until now there is no established standard treatment protocol for chronic CSC.
Bevacizumab (Avastin) and ranibizumab (Lucentis) have been used widely as anti-VEGF therapeutic agent for the treatment of age related macular generation (AMD) and macular edema of various reasons. A newly developed anti-VEGF drug, aflibercept (Eylea○R), shows higher affinity to VEGF and has a longer duration of effect in the vitreous.FDA approved aflibercept to treat wet type AMD and macular edema due to central retinal vein occlusion.
Until now, no study has been reported on the efficacy and safety of aflibercept for treating CSC. The aim of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection for the treatment of idiopathic CSC
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy
NCT05687422
Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
NCT03339856
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
NCT01019668
Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy
NCT05662410
Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment
NCT02381730
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group A : 2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month Group B : Sham injection at baseline, at 1 month, and at 2 month
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
3. Central subfield thickness is thicker than the previous exam
4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sham injection
Sham injection at baseline, at 1 month, and at 2 month
Sham injection
Sham injection at baseline, at 1 month, and at 2 month.
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
3. Central subfield thickness is thicker than the previous exam
4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Half-fluence photodynamic therapy
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
3. Central subfield thickness is thicker than the previous exam
4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Intravitreal Aflibercept injection
2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month
Intravitreal Aflibercept injection
2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
3. Central subfield thickness is thicker than the previous exam
4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Half-fluence photodynamic therapy
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
3. Central subfield thickness is thicker than the previous exam
4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravitreal Aflibercept injection
2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
3. Central subfield thickness is thicker than the previous exam
4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Sham injection
Sham injection at baseline, at 1 month, and at 2 month.
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
3. Central subfield thickness is thicker than the previous exam
4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Half-fluence photodynamic therapy
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
3. Central subfield thickness is thicker than the previous exam
4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 to 60 years old, woman and man.
* Subretinal fluid is found at OCT.
* Symptom duration is from 6 weeks to 4 months.
* Patient who agree to participate in the study.
Exclusion Criteria
* Patient who has choroidal neovascularization or other macular disease
* Patient who has other ophthalmologic disease that may affect patient's vision.
* History of any intraocular surgery, except cataract extraction prior to 3 months
* Patient who has active intraocular inflammation or infection
* Patient who has uncontrolled glaucoma IOP was more than 25 mmHg in spite of anti-glaucoma medication Visual field defect which affect best corrected visual acuity
* Patient who has been used systemic or topical carbonic anhydrase inhibitor within 1 month
* Cushing syndrome
* History of intravitreal steroid injection to study eye
* Patient who has been used or plan to use systemic drug which is toxic to crystalline lens, retina or optic nerve.
* Patient who has a known allergy to fluorescein or ICG
* Pregnant or breast-feeding woman
* Patient with contraindication to aflibercept Ocular or periocular infection Active severe intraocular inflammation Known hypersensitivity to aflibercept or to any of the excipients
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young Hee Yoon
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young Hee Yoon, MD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chungbuk national hospital
Chungju, , South Korea
Gangneung asan hospital
Gangneung, , South Korea
Seoul national university Bundang Hospital
Ilsan, , South Korea
Asan medical center
Seoul, , South Korea
Kim's Eye Hospital
Seoul, , South Korea
Samsung seoul hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dohrmann J, Lommatzsch A, Spital G, Pauleikhoff D. [Pathogenesis of central serous chorioretinopathy: angiographic and electrophysiological studies]. Ophthalmologe. 2001 Nov;98(11):1069-73. doi: 10.1007/s003470170027. German.
Wong R, Chopdar A, Brown M. Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy. Eye (Lond). 2004 Mar;18(3):262-8. doi: 10.1038/sj.eye.6700637.
Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203-13. doi: 10.1097/00006982-199616030-00004.
Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011 Nov;152(5):784-92.e2. doi: 10.1016/j.ajo.2011.04.008. Epub 2011 Jul 13.
Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol. 2011 May;89(3):e293-4. doi: 10.1111/j.1755-3768.2009.01835.x. No abstract available.
Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2011 Jul;249(7):969-74. doi: 10.1007/s00417-010-1581-9. Epub 2010 Dec 8.
Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2012 Nov;56(6):608-12. doi: 10.1007/s10384-012-0162-3. Epub 2012 Aug 23.
Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012 Aug;154(2):222-6. doi: 10.1016/j.ajo.2012.04.020.
Frampton JE. Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. Drugs Aging. 2012 Oct;29(10):839-46. doi: 10.1007/s40266-012-0015-2.
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8. doi: 10.1073/pnas.172398299. Epub 2002 Aug 12.
Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013 Mar;155(3):429-437.e7. doi: 10.1016/j.ajo.2012.09.026. Epub 2012 Dec 4.
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17.
Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012 May;119(5):1024-32. doi: 10.1016/j.ophtha.2012.01.042. Epub 2012 Mar 21.
Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS; da Vinci Study Group. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012 Aug;119(8):1658-65. doi: 10.1016/j.ophtha.2012.02.010. Epub 2012 Apr 24.
Lange CA, Qureshi R, Pauleikhoff L. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AFECT_001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.